Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06441643 · ClinicalTrials.gov registry record · Phase 2
Next Generation Rocklatan
A Phase 2 study, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 426
- Enrollment target
NCT06441643 is a Phase 2 study that has completed, run by Alcon Research. The registered enrollment target is 426 participants.
The verdict
NCT06441643, a Phase 2 study, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 426 participants
- Enrollment target
Study Summary
The purpose of this two-stage clinical trial is to assess the safety and hypotensive efficacy of AR-17043 and PG043 ophthalmic solutions in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT).
Interventions
- DRUG Latanoprost 0.005% Ophthalmic Solution
- DRUG Netarsudil 0.02% Ophthalmic Solution
- DRUG AR-17043 Ophthalmic Solution
- DRUG PG043 Ophthalmic Solution
- DRUG Netarsudil 0.02%/Latanoprost 0.005% Ophthalmic Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 426 participants |
| Start Date | 2024-09-04 |
| Est. Completion | 2025-11-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06441643
The ClinicalTrials.gov registry entry for NCT06441643 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 426 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alcon Research, which has 275 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Latanoprost 0.005% Ophthalmic Solution is the first listed.
NCT06441643 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06441643 about?
NCT06441643 is a clinical study titled "Next Generation Rocklatan". The purpose of this two-stage clinical trial is to assess the safety and hypotensive efficacy of AR-17043 and PG043 ophthalmic solutions in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT).
What is the current status of trial NCT06441643?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 426 participants. The study started on 2024-09-04. Estimated completion is 2025-11-14.
What interventions are being tested in trial NCT06441643?
The interventions under investigation include: Latanoprost 0.005% Ophthalmic Solution (DRUG), Netarsudil 0.02% Ophthalmic Solution (DRUG), AR-17043 Ophthalmic Solution (DRUG), PG043 Ophthalmic Solution (DRUG), Netarsudil 0.02%/Latanoprost 0.005% Ophthalmic Solution (DRUG).
Who is sponsoring clinical trial NCT06441643?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.